Carlsmed

Carlsmed's mission is to improve patient outcomes and decrease the cost of healthcare in spine surgery by shifting from standard implants to a fully personalized approach. The company has achieved significant commercial traction with its FDA-cleared aprevo® platform, reporting $50.5 million in revenue for FY 2025, representing 86% year-over-year growth. Its strategy centers on expanding its personalized implant portfolio, generating robust clinical evidence, and leveraging its integrated digital platform to drive adoption in the large and growing spine surgery market.

The aprevo® platform is an end-to-end, AI-enabled system that uses patient CT scans to create personalized 3D surgical plans and manufactures patient-specific spinal implants via 3D printing, integrating pre-op planning, intra-op guidance, and post-op analytics.